All In Biotech

Drug Trial Radar · NCT06989788

A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, in Healthy Adults

A Randomised, Double-blind, Placebo-controlled, Single Centre, Phase I Study to Evaluate the Safety, Reactogenicity and Immunogenicity of AstriVax' Investigational Therapeutic Hepatitis B Virus (HBV) Vaccine (AVX70371) in Healthy Adults Aged 18 to 40 Years

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

May 6, 2025

Primary completion

Aug 10, 2026

Study completion Aug 10, 2026

Sponsor

Lead sponsor
AstriVax TherapeuticsIndustry
Sponsor type
Industry
First posted
May 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this first time in humans trial is to evaluate the safety, reactogenicity and immunogenicity of repeated administrations of AVX70371 in healthy participants.

Conditions

  • Chronic Hepatitis b

Interventions

  • AVX70371Biological

    AstriVax Therapeutics' HBV immunotherapeutic

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of solicited adverse eventsTime frame: During a 14-day follow-up period after each administration
  2. Occurrence of unsolicited adverse eventsTime frame: From Day 1 up to 1 month after the last administration
  3. Occurrence of hematological and biochemical laboratory abnormalitiesTime frame: From Day 1 up to 1 month after the last administration
  4. Occurrence of adverse events of special interestTime frame: From Day 1 up to 1 year after the last administration
  5. Occurrence of serious adverse eventsTime frame: From Day 1 up to 1 year after the last administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital Ghent - Centrum voor Vaccinologie (CEVAC)

    Ghent, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.